Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Value AnalystHold
Overall Rating4/10
Generated at:2026-03-04 16:37:07
Analysis based on 5 financial reports: 2025-09-30, 2025-06-30, 2025-03-31, 2024-12-31, 2024-09-30. Data includes quarterly financial metrics, valuation indicators, and market price data as of 2026-03-05. Complete financial analysis covering liquidity, leverage, revenue trends, and profitability metrics.
Overview

Moderna is a biotechnology company transitioning from pandemic-driven revenue to developing its next-generation pipeline of mRNA therapeutics and vaccines. The company faces challenges with declining COVID-19 vaccine sales but maintains strong liquidity and research capabilities. While financial condition is robust with low debt and ample cash reserves, profitability remains negative due to high R&D costs and revenue contraction.

Valuation
3/10
Profitability
2/10
Financial health
7/10
Operation Advice
  • Hold position with tight stop-losses around $45.
  • Consider phased entry to mitigate volatility.
  • Monitor pipeline catalysts such as new vaccine approvals (RSV, influenza) for potential upside opportunities.
  • High risk due to negative earnings and revenue declines.

Valuation

P/E TTM
-5.88
P/E LYR
-5.14
P/B MRQ
1.96
P/S TTM
--
AI Analysis
  • Valuation relies on pipeline potential rather than current earnings, with negative PE ratios and high PS ratio reflecting market optimism. Moderate PB ratio suggests reasonable asset-based valuation with target price of $70-75 contingent on successful pipeline execution.
  • Current price $57.80 as of 2026-03-05
  • Negative TTM PE (-5.88) and forward PE (-5.14) indicate no earnings support
  • PB ratio of 1.96 suggests moderate asset-based valuation
  • High PS-TTM (10.42) reflects market optimism beyond current sales
  • Stock has shown volatility with $22.36–$59.55 range over 60 days
  • Short-term price range: $45–$65 (support near $45, resistance near $65)
  • Medium-term price range: $40–$75 contingent on pipeline progress
  • Target price: $70–$75 assuming successful pipeline execution
Valuation trend

Profitability

ROE TTM
-29.57%
Net margin
-157.66%
Gross margin
67.14%
Total revenue
1.27B
AI Analysis
  • Consistent losses with negative EPS driven by high R&D costs and revenue contraction. Margin volatility and negative ROE/ROA reflect inefficient capital utilization during transitional phase.
  • Consistent losses with negative EPS (Q3 2025: -$5.15; TTM PE: -5.88)
  • Driven by high R&D costs and revenue contraction
  • Gross margins fluctuated widely (Q2 2025: 16.40%; Q3 2025: 67.14%)
  • Net margins remain deeply negative (-157.66% in Q3 2025)
  • ROE (-29.57%) and ROA (-22.80%) reflect inefficient capital utilization
  • Profitability recovery hinges on successful commercialization of new products
  • Near-term challenges persist despite pipeline potential
Profitability
2024Q32024Q42025Q12025Q22025Q3
ROE TTM---28.77%-9.26%-17.69%-29.57%
Earnings
2024Q32024Q42025Q12025Q22025Q3
Total revenue2.27B3.24B108.00M250.00M1.27B

Financial health

Debt/Asset
23.11%
Current ratio
3.92
Quick ratio
3.73
Cash ratio
3.73
AI Analysis
  • Strong short-term financial position with robust liquidity metrics, low debt levels, and substantial cash reserves. However, significant revenue decline observed across recent quarters due to reduced COVID-19 vaccine demand.
  • Strong liquidity metrics with current ratio of 3.92 and quick ratio of 3.73
  • Low debt levels with 23.11% debt-to-asset ratio reflecting conservative capital structure
  • Significant revenue decline observed across recent quarters
  • Q3 2025 revenue of $1.27B, down 44.23% YoY primarily due to reduced COVID-19 vaccine demand
  • Substantial cash reserves from pandemic-era sales supporting ongoing R&D investments
  • Robust short-term financial position despite profitability challenges
Leverage
2024Q32024Q42025Q12025Q22025Q3
Debt/Asset24.53%22.92%20.77%21.74%23.11%
Liquidity
2024Q32024Q42025Q12025Q22025Q3
Current ratio4.393.674.223.933.92